Distilling Cancer Biomarkers From the Serum Peptidome: High Technology Reading of Tea Leaves or an Insight to Clinical Systems Biology?
- 1 August 2005
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (22) , 4835-4837
- https://doi.org/10.1200/jco.2005.02.912
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma PatientsJournal of Clinical Oncology, 2005
- Serum Proteomic Profiles Suggest Celecoxib-Modulated Targets and Response PredictorsCancer Research, 2004
- Serum Peptide Profiling by Magnetic Particle-Assisted, Automated Sample Processing and MALDI-TOF Mass SpectrometryAnalytical Chemistry, 2004
- Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experimentsBioinformatics, 2004
- Identification of Patients With Head and Neck Cancer Using Serum Protein ProfilesJAMA Otolaryngology–Head & Neck Surgery, 2004
- Development of Proteomic Patterns for Detecting Lung CancerDisease Markers, 2003
- Proteomics and Bioinformatics Approaches for Identification of Serum Biomarkers to Detect Breast CancerClinical Chemistry, 2002
- Use of proteomic patterns in serum to identify ovarian cancerPublished by Elsevier ,2002